Invivyd Inc. Secures $30M Loan Facility with Silicon Valley Bank

In a significant development for the biotechnology sector, Invivyd, Inc., a company based in Waltham, United States, has announced a substantial non-dilutive loan facility with Silicon Valley Bank. This $30 million loan marks a pivotal moment for the company, which specializes in developing next-generation candidate antibodies aimed at the prevention and treatment of COVID-19.

Invivyd’s strategic focus is on advancing two specific molecules, known as NVD200, through near-term clinical development for combined use. This initiative underscores the company’s commitment to addressing global health challenges and expanding its reach to serve customers worldwide. The company’s official website, www.invivyd.com , provides further insights into its mission and ongoing projects.

The financial boost from Silicon Valley Bank is expected to bolster Invivyd’s research and development efforts, potentially accelerating the clinical trials and bringing its innovative solutions closer to market. This move is particularly noteworthy given the company’s recent stock performance. Over the past year, Invivyd’s stock has experienced fluctuations, ranging from a low of 0.355 USD to a high of 2.74 USD. As of May 4, 2025, the stock closed at 0.575 USD, reflecting a moderate recovery from its 52-week low.

Trading on the Nasdaq, Invivyd’s financial journey has been marked by both challenges and opportunities. The recent loan facility is a testament to the company’s resilience and the confidence that financial institutions like Silicon Valley Bank have in its potential. As Invivyd continues to navigate the complexities of the biotechnology landscape, this financial support could play a crucial role in its pursuit of groundbreaking healthcare solutions.

For investors and stakeholders, this development signals a promising horizon for Invivyd, Inc. The company’s ability to secure such a significant loan without diluting its equity is a strategic advantage, allowing it to maintain control over its operations while pursuing ambitious goals. As Invivyd moves forward, the biotechnology community will be watching closely to see how this financial infusion impacts its trajectory in the fight against COVID-19 and beyond.